{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:38:22Z","timestamp":1792460302578,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.amjcard.2026.06.008","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:06:18Z","timestamp":1780985178000},"page":"59-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["GLP-1 Receptor Agonists and Primary Prevention of Cancer Therapy-Related Cardiac Dysfunction"],"prefix":"10.1016","volume":"273","author":[{"given":"Syed Sarmad","family":"Javaid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Hanif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Paulson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus S","family":"Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas W.S.","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeena","family":"Jamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Michael","family":"DiMaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shahzeb","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2026.06.008_bib0001","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1158\/1055-9965.EPI-12-1356","article-title":"Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care","volume":"22","author":"de Moor","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0002","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jaccao.2022.01.101","article-title":"The role of cardioprotection in cancer therapy cardiotoxicity: JACC: CardioOncology state-of-the-art review","volume":"4","author":"Omland","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0003","doi-asserted-by":"crossref","DOI":"10.1177\/1179546819866445","article-title":"Cancer therapy-related cardiac dysfunction: an overview for the clinician","volume":"13","author":"Perez","year":"2019","journal-title":"Clin Med Insights Cardiol"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0004","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.3390\/biomedicines12122914","article-title":"Cancer therapy-related cardiac dysfunction: a review of current trends in epidemiology, diagnosis, and treatment","volume":"12","author":"Theofilis","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0005","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jjcc.2022.04.006","article-title":"Cancer therapeutics-related cardiovascular dysfunction: basic mechanisms and clinical manifestation","volume":"81","author":"Oikawa","year":"2023","journal-title":"J Cardiol"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0006","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"23","author":"Lyon","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0007","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaccao.2024.08.001","article-title":"SGLT2i and primary prevention of cancer therapy-related cardiac dysfunction in patients with diabetes","volume":"6","author":"Bhatti","year":"2024","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0008","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/antiox13010016","article-title":"Anti-inflammation and anti-oxidation: the key to unlocking the cardiovascular potential of SGLT2 inhibitors and GLP1 receptor agonists","volume":"13","author":"Myasoedova","year":"2023","journal-title":"Antioxidants (Basel)."},{"key":"10.1016\/j.amjcard.2026.06.008_bib0009","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/dom.12982","article-title":"Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor","volume":"19","author":"DeFronzo","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0010","doi-asserted-by":"crossref","first-page":"103129","DOI":"10.1016\/j.redox.2024.103129","article-title":"Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating BNIP3-mediated mitochondrial dysfunction","volume":"72","author":"Li","year":"2024","journal-title":"Redox Biol"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0011","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0012","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0013","unstructured":"TriNetX. Accessed February 2020. https:\/\/www.trinetx.com"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0014","article-title":"A harmonized data quality assessment terminology and framework for the secondary use of electronic health record data","volume":"4","author":"Kahn","year":"2016","journal-title":"EGEMS (Wash DC)"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0015","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/jamasurg.2021.0528","article-title":"STROBE reporting guidelines for observational studies","volume":"156","author":"Ghaferi","year":"2021","journal-title":"JAMA Surg"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0016","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0017","doi-asserted-by":"crossref","first-page":"812","DOI":"10.21037\/atm-20-3998","article-title":"Propensity score matching with R: conventional methods and new features","volume":"9","author":"Zhao","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0018","doi-asserted-by":"crossref","first-page":"115170","DOI":"10.1016\/j.ejca.2024.115170","article-title":"Glucagon-like peptide-1 agonists reduce cardiovascular events in cancer patients on immune checkpoint inhibitors","volume":"216","author":"Chiang","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0019","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.3390\/cancers17091593","article-title":"Survival benefits of GLP-1 receptor agonists in patients with neuroendocrine neoplasms: a large-scale propensity-matched cohort study","volume":"17","author":"Fawzy","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0020","doi-asserted-by":"crossref","DOI":"10.3390\/diseases12050096","article-title":"Factors affecting survival outcomes in neuroendocrine tumor of the appendix over the past two decades","volume":"12","author":"Nagesh","year":"2024","journal-title":"Diseases"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0021","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s10555-024-10192-9","article-title":"The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer","volume":"43","author":"Ibrahim","year":"2024","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0022","first-page":"1","article-title":"Involvement of interleukin-6 induced PI3K\/akt\/mTor pathway in the regulation of telomerase and alpha-fetoprotein expression in hepatocellular carci-noma","volume":"6","author":"Hilal","year":"2023","journal-title":"Clin Onco"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0023","doi-asserted-by":"crossref","first-page":"106320","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0024","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2147\/DMSO.S193693","article-title":"Comparative effectiveness of long-acting GLP-1 receptor agonists in type 2 diabetes: a short review on the emerging data","volume":"13","author":"Chudleigh","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0025","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/oby.23621","article-title":"Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics","author":"Lingvay","year":"2023","journal-title":"Obesity"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0026","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jchf.2023.08.026","article-title":"SGLT2 Inhibitor use and risk of clinical events in patients with cancer therapy-related cardiac dysfunction","volume":"12","author":"Avula","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0027","first-page":"6013","article-title":"Assessment of the cardioprotective effect of liraglutide on methotrexate induced cardiac dysfunction through suppression of inflammation and enhancement of angiogenesis in rats","volume":"25","author":"Mahmoud","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0028","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fendo.2018.00672","article-title":"Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function","volume":"9","author":"Rowlands","year":"2018","journal-title":"Front Endocrinol (Lausanne)."},{"key":"10.1016\/j.amjcard.2026.06.008_bib0029","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jsps.2020.03.002","article-title":"Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK\/NF-\u03baB signaling pathways","volume":"28","author":"AlAsmari","year":"2020","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0030","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2147\/CMAR.S468453","article-title":"Effects of semaglutide in doxorubicin-induced cardiac toxicity in Wistar Albino rats","volume":"16","author":"HamaSalih","year":"2024","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0031","doi-asserted-by":"crossref","first-page":"590768","DOI":"10.3389\/fcvm.2021.590768","article-title":"Atrial fibrillation and cancer","volume":"8","author":"Hajjar","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0032","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jacc.2013.11.026","article-title":"Insights into onco-cardiology: atrial fibrillation in cancer","volume":"63","author":"Farmakis","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0033","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.diabres.2015.07.015","article-title":"Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"110","author":"Sun","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0034","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001986","article-title":"Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis","volume":"3","author":"Robinson","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0035","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/672658","article-title":"Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis","volume":"2012","author":"Monami","year":"2012","journal-title":"Exp Diabetes Res"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0036","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential","volume":"17","author":"Ma","year":"2021","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0037","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0038","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/ckj\/sfae296","article-title":"GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity","volume":"17","author":"Abasheva","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0039","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.50408","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk in patients with type 2 diabetes","volume":"7","author":"Dankner","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.amjcard.2026.06.008_bib0040","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s11255-024-04266-4","article-title":"Effect of GLP-1 receptor agonists on prostate cancer risk reduction: a systematic review and meta-analysis","volume":"57","author":"Sharma","year":"2025","journal-title":"Int Urol Nephrol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000291492600398X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000291492600398X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T12:02:36Z","timestamp":1785326556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000291492600398X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":40,"alternative-id":["S000291492600398X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.06.008","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 Receptor Agonists and Primary Prevention of Cancer Therapy-Related Cardiac Dysfunction","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}